Evidence map›Paper›PMID 28102310›Full record

ArticleScientific reports2017

Coordinated cell motility is regulated by a combination of LKB1 farnesylation and kinase activity.

S Wilkinson, Y Hou, J T Zoine, J Saltz, C Zhang, Z Chen, L A D Cooper, A I Marcus

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.Cell communication and signaling : CCS · 2024
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

S WilkinsonWinship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA.
Y HouWinship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA.
J T ZoineWinship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA.
J SaltzDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA.
C ZhangDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
Z ChenDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
L A D CooperWinship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA.
A I MarcusWinship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA, USA.
Emory University · USPiedmont Cancer Institute · USStony Brook University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Image Mining for Comparative Analysis of Expression Patterns in Tissue MicroarrayR01LM009239 · NLM · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI FORAN, DAVID J, SALTZ, JOEL H. · 2007 to 2016
$4.5M
Advanced Development of an Open-source Platform for Web-based Integrative Digital Image Analysis in CancerU24CA194362 · NCI · EMORY UNIVERSITY · PI COOPER, LEE, GUTMAN, DAVID ANDREW · 2015 to 2019
$3.6M
Tools to Analyze Morphology and Spatially Mapped Molecular DataU24CA180924 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI SALTZ, JOEL H. · 2014 to 2019
$3.6M
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patientsR01CA194027 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.5M
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0M
Control of lung cancer invasion and metastasis by vimentinR01CA142858 · NCI · EMORY UNIVERSITY · PI MARCUS, ADAM I. · 2011 to 2015
$1.6M
Multiscale Framework for Molecular Heterogeneity AnalysisK22LM011576 · NLM · EMORY UNIVERSITY · PI COOPER, LEE · 2013 to 2015
$485k
Defining the role of farnesylated LKB1 in regulating cell polarity and invasionF31CA200383 · NCI · EMORY UNIVERSITY · PI WILKINSON, SCOTT · 2015 to 2016
$87k
NCI NIH HHS F31 CA200383NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA142858NCI NIH HHS R01 CA194027NCI NIH HHS R01 CA201340NCI NIH HHS U24 CA180924NCI NIH HHS U24 CA194362NLM NIH HHS K22 LM011576NLM NIH HHS R01 LM009239
6 · The paper itself

Abstract

Cell motility requires the precise coordination of cell polarization, lamellipodia formation, adhesion, and force generation. LKB1 is a multi-functional serine/threonine kinase that associates with actin at the cellular leading edge of motile cells and suppresses FAK. We sought to understand how LKB1 coordinates these multiple events by systematically dissecting LKB1 protein domain function in combination with live cell imaging and computational approaches. We show that LKB1-actin colocalization is dependent upon LKB1 farnesylation leading to RhoA-ROCK-mediated stress fiber formation, but membrane dynamics is reliant on LKB1 kinase activity. We propose that LKB1 kinase activity controls membrane dynamics through FAK since loss of LKB1 kinase activity results in morphologically defective nascent adhesion sites. In contrast, defective farnesylation mislocalizes nascent adhesion sites, suggesting that LKB1 farnesylation serves as a targeting mechanism for properly localizing adhesion sites during cell motility. Together, we propose a model where coordination of LKB1 farnesylation and kinase activity serve as a multi-step mechanism to coordinate cell motility during migration.

Indexed as

ActinsAmidesAMP-Activated Protein Kinase KinasesCell AdhesionCell MembraneCell MovementFocal Adhesion Kinase 1HeLa CellsHumansIndolesMicroscopy, FluorescenceMutagenesis, Site-DirectedPrenylationProtein DomainsProtein Serine-Threonine KinasesPyridinesActinsAmidesAMP-Activated Protein Kinase KinasesFocal Adhesion Kinase 1IndolesN-methyl-N-(3-((2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl)-pyridin-2-yl)-methanesulfonamideProtein Serine-Threonine KinasesPyridinesrhoA GTP-Binding ProteinSTK11 protein, humanSulfonamidesY 27632

Identifiers

PMID28102310
PMCPMC5244416
OpenAlexW2575217172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.